Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 451 Melanoma 287 Squamous Cell Carcinoma of Head and Neck 229 Parkinson Disease 4, Autosomal Dominant Lewy Body 188 Neoplasms 180 Triple Negative Breast Neoplasms 162 Breast Neoplasms 161 Neoplasm Metastasis 156 Lung Neoplasms 141 Colorectal Neoplasms 140 Carcinoma, Renal Cell 129 Head and Neck Neoplasms 120 Stomach Neoplasms 103 Ovarian Neoplasms 101 Carcinoma, Transitional Cell 92 Urinary Bladder Neoplasms 80 Pancreatic Neoplasms 80 Endometrial Neoplasms 74 Carcinoma, Hepatocellular 72 Uterine Cervical Neoplasms 63 Esophageal Neoplasms 57 Recurrence 52 Prostatic Neoplasms 48 Sarcoma 43 Carcinoma 42 Small Cell Lung Carcinoma 39 Glioblastoma 39 Carcinoma, Squamous Cell 39 Hodgkin Disease 36 Lymphoma 34

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × pembrolizumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡